Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05756569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05756569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2023
Completion date
December 16, 2027
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder adenocarcinoma, bladder squamous cell carcinoma, locally advanced bladder carcinoma, malignant renal pelvis neoplasm, malignant ureter neoplasm, malignant urethral neoplasm, metastatic bladder carcinoma, stage iii bladder cancer ajcc v8, stage iv bladder cancer ajcc v8, unresectable bladder carcinoma, urachal adenocarcinoma